Suppr超能文献

胚系乳腺癌易感基因、肿瘤特征和生存。

Germline breast cancer susceptibility genes, tumor characteristics, and survival.

机构信息

Genome Institute of Singapore, Human Genetics, Singapore, Singapore.

Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore.

出版信息

Genome Med. 2021 Dec 2;13(1):185. doi: 10.1186/s13073-021-00978-9.

Abstract

BACKGROUND

Mutations in certain genes are known to increase breast cancer risk. We study the relevance of rare protein-truncating variants (PTVs) that may result in loss-of-function in breast cancer susceptibility genes on tumor characteristics and survival in 8852 breast cancer patients of Asian descent.

METHODS

Gene panel sequencing was performed for 34 known or suspected breast cancer predisposition genes, of which nine genes (ATM, BRCA1, BRCA2, CHEK2, PALB2, BARD1, RAD51C, RAD51D, and TP53) were associated with breast cancer risk. Associations between PTV carriership in one or more genes and tumor characteristics were examined using multinomial logistic regression. Ten-year overall survival was estimated using Cox regression models in 6477 breast cancer patients after excluding older patients (≥75years) and stage 0 and IV disease.

RESULTS

PTV carriership (n = 690) was significantly associated (p < 0.001) with more aggressive tumor characteristics including high grade (poorly vs well-differentiated, odds ratio [95% confidence interval] 3.48 [2.35-5.17], moderately vs well-differentiated 2.33 [1.56-3.49]), as well as luminal B [HER-] and triple-negative subtypes (vs luminal A 2.15 [1.58-2.92] and 2.85 [2.17-3.73], respectively), adjusted for age at diagnosis, study, and ethnicity. Associations with grade and luminal B [HER2-] subtype remained significant after excluding BRCA1/2 carriers. PTV carriership (n = 289, excluding carriers of the nine genes associated with breast cancer) was not associated with tumor characteristics. However, PTV carriership, but not PTV carriership, was suggested to be associated with worse 10-year overall survival (hazard ratio [CI] 1.63 [1.16-2.28]).

CONCLUSIONS

PTV carriership is associated with more aggressive tumors. Variants in other genes might be associated with the survival of breast cancer patients. The finding that PTV carriership is not just associated with higher breast cancer risk, but also more severe and fatal forms of the disease, suggests that genetic testing has the potential to provide additional health information and help healthy individuals make screening decisions.

摘要

背景

已知某些基因的突变会增加乳腺癌风险。我们研究了在 8852 名亚洲裔乳腺癌患者中,可能导致乳腺癌易感性基因功能丧失的罕见蛋白截断变异(PTV)与肿瘤特征和生存的相关性。

方法

对 34 个已知或疑似乳腺癌易感性基因进行基因panel 测序,其中 9 个基因(ATM、BRCA1、BRCA2、CHEK2、PALB2、BARD1、RAD51C、RAD51D 和 TP53)与乳腺癌风险相关。使用多项逻辑回归检查一个或多个基因中 PTV 携带者与肿瘤特征之间的关系。在排除年龄较大(≥75 岁)和 0 期和 IV 期疾病的 6477 名乳腺癌患者中,使用 Cox 回归模型估计 10 年总生存率。

结果

PTV 携带者(n=690)与更具侵袭性的肿瘤特征显著相关(p<0.001),包括高分级(差 vs 高分化,比值比[95%置信区间]3.48[2.35-5.17],中 vs 高分化 2.33[1.56-3.49]),以及管腔 B[HER-]和三阴性亚型(与管腔 A 相比分别为 2.15[1.58-2.92]和 2.85[2.17-3.73]),调整诊断时年龄、研究和种族。在排除 BRCA1/2 携带者后,与分级和管腔 B[HER2-]亚型的关联仍然显著。PTV 携带者(n=289,不包括与乳腺癌相关的九个基因的携带者)与肿瘤特征无关。然而,PTV 携带者与较差的 10 年总生存率相关(风险比[CI]1.63[1.16-2.28]),但 PTV 携带者与较差的 10 年总生存率相关。

结论

PTV 携带者与更具侵袭性的肿瘤相关。其他基因的变异可能与乳腺癌患者的生存相关。PTV 携带者不仅与更高的乳腺癌风险相关,而且与更严重和致命的疾病形式相关的发现表明,基因检测有可能提供额外的健康信息,并帮助健康个体做出筛查决策。

相似文献

1
Germline breast cancer susceptibility genes, tumor characteristics, and survival.
Genome Med. 2021 Dec 2;13(1):185. doi: 10.1186/s13073-021-00978-9.
2
Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes.
JAMA Oncol. 2022 Mar 1;8(3):e216744. doi: 10.1001/jamaoncol.2021.6744. Epub 2022 Mar 17.
3
The impact of coding germline variants on contralateral breast cancer risk and survival.
Am J Hum Genet. 2023 Mar 2;110(3):475-486. doi: 10.1016/j.ajhg.2023.02.003. Epub 2023 Feb 23.
5
Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.
N Engl J Med. 2021 Feb 4;384(5):428-439. doi: 10.1056/NEJMoa1913948. Epub 2021 Jan 20.
7
Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
JAMA Oncol. 2017 Sep 1;3(9):1190-1196. doi: 10.1001/jamaoncol.2017.0424.
8
Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.
PLoS One. 2016 Jun 3;11(6):e0156789. doi: 10.1371/journal.pone.0156789. eCollection 2016.
10
Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
Breast. 2022 Oct;65:32-40. doi: 10.1016/j.breast.2022.06.003. Epub 2022 Jun 18.

本文引用的文献

2
Intronic Breakpoint Signatures Enhance Detection and Characterization of Clinically Relevant Germline Structural Variants.
J Mol Diagn. 2021 May;23(5):612-629. doi: 10.1016/j.jmoldx.2021.01.015. Epub 2021 Feb 20.
3
Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.
N Engl J Med. 2021 Feb 4;384(5):428-439. doi: 10.1056/NEJMoa1913948. Epub 2021 Jan 20.
5
Clinical use of current polygenic risk scores may exacerbate health disparities.
Nat Genet. 2019 Apr;51(4):584-591. doi: 10.1038/s41588-019-0379-x. Epub 2019 Mar 29.
6
Polygenic risk scores: a biased prediction?
Genome Med. 2018 Dec 27;10(1):100. doi: 10.1186/s13073-018-0610-x.
7
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes.
Am J Hum Genet. 2019 Jan 3;104(1):21-34. doi: 10.1016/j.ajhg.2018.11.002. Epub 2018 Dec 13.
9
Burden Testing of Rare Variants Identified through Exome Sequencing via Publicly Available Control Data.
Am J Hum Genet. 2018 Oct 4;103(4):522-534. doi: 10.1016/j.ajhg.2018.08.016. Epub 2018 Sep 27.
10
Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis.
Genes Dis. 2018 May 12;5(2):77-106. doi: 10.1016/j.gendis.2018.05.001. eCollection 2018 Jun.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验